Carotid stent developer InspireMD (Nasdaq:NSPR) announced today that it appointed Dan Dearen to its board of directors.
Dearen, a longtime medtech veteran, notably served as co-founder, president and CFO of Axonics. He joins fellow Axonics co-founder and former CEO, Raymond Cohen, on the InspireMD board. Axonics was acquired by Boston Scientific for $3.7 billion last year.
(Join us at DeviceTalks West — Oct. 15–16, 2025, in Santa Clara, California — to hear our keynote interview with Cohen. Register at West.DeviceTalks.com.)
According to a news release, Dearen has nearly 40 years of leadership experience in the medical device and life sciences sector. His track record includes guiding medtech companies through critical financial milestones and delivering shareholder value.
“We are pleased to welcome Dan to InspireMD’s Board of Directors,” said Marvin Slosman, Chief Executive Officer of InspireMD. “He brings extensive experience, financial expertise, and strategic insight to InspireMD as we advance on our mission to lead the carotid intervention market and execute our long-term value-creation strategy. His arrival is perfectly timed as we continue our U.S. commercial launch of CGuard Prime and advance our position in the market.”
Dearen retired from his post as CFO at Axonics in 2023. Until last year, he served as chair on the audit committee and as a board member at Endotronix. He also holds the same roles at JenaValve and Beta Bionics. Before co-founding Axonics, Dearen held the post of COO and CFO of Vessix Vascular before Boston Scientific acquired it in 2012.
“With FDA approval for the CGuard Prime stent system in hand, InspireMD has the potential to change the standard of care in vascular medicine and greatly improve the lives of patients,” said Dearen. “This is a remarkable time for the company, and I look forward to supporting the team through this vast opportunity for growth.”
InspireMD received FDA premarket approval for its CGuard Prime carotid stent in June. The embolic prevention stent (EPS) system utilizes the company’s MicroNet technology for strong acute results and durable, stroke-free, long-term outcomes.
